Table 2 Cases and deaths averted, incremental costs, DALYs averted and net health benefit compared to baseline no vaccination scenario—default case.

From: Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis

Strategy

Cases averted

Deaths averted

Incremental cost, USD millions

DALYs averted, thousands

Mean net health benefit, DALYs averted,thousands (probability of cost-effectiveness)

Lower HCOC

Upper HCOC

Mass&Routine18–50

315,256

61,718

321

954

841 (0%)

874 (0%)

2xMass18–50

490,008

96,417

417

1345

1201 (65%)

1244 (70%)

Mass&RoutineAdultHIV+

209,524

42,143

41

628

712 (0%)

716 (0%)

2xMassAdultHIV+

367,862

73,191

49

948

1112 (35%)

1116 (30%)

  1. Estimates are medians unless specified otherwise. Mass&Routine18–50—mass campaign for people aged 18–50 & routine vaccination for 18-year olds; 2xMass18–50—two mass campaigns for people aged 18–50; Mass&RoutineAdultsHIV+ mass campaign for all adults living with HIV & routine vaccination of 18-year olds living with HIV; 2xMassAdultsHIV+ two mass campaigns for all adults living with HIV. Net health benefit threshold based on health-care opportunity cost (HCOC) threshold for South Africa. Lower HCOC threshold for SA, $2,480. Upper HCOC threshold for SA, $3,334. Default-case: vaccine disease efficacy = 50%; duration of protection = 5 years; routine coverage = 40% (70% for HIV+ only campaigns); mass coverage 60%.
Back to article page